Tirzepatide 10mg – Technical Product Description

Tirzepatide 10mg is a synthetic, long-acting dual incretin receptor agonist peptide engineered to target both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This novel peptide sequence consists of 39 amino acids with a C20 fatty diacid moiety conjugated through a linker structure, enabling extended half-life and prolonged biological activity through albumin binding. Tirzepatide is designed for once-weekly administration protocols and has demonstrated high receptor affinity with enhanced metabolic signaling characteristics.

The peptide exhibits dual agonist functionality by activating GIP and GLP-1 pathways involved in glucose regulation, insulin secretion, gastric emptying modulation, and appetite signaling. Its mechanism of action supports glucose-dependent insulin release while reducing glucagon secretion and delaying gastric transit. Due to its dual receptor activity profile, tirzepatide has become a prominent compound within metabolic and peptide research applications.

Each vial contains 10mg of lyophilized tirzepatide peptide prepared under sterile processing conditions. The lyophilized format is intended to support peptide stability during storage and transportation prior to reconstitution. Product appearance typically consists of a white to off-white freeze-dried cake or powder with high purity manufacturing standards suitable for laboratory and research environments.

Technical Specifications

• Compound Name: Tirzepatide
• Molecular Formula: C225H348N48O68
• Molecular Weight: Approximately 4813.45 g/mol
• Peptide Type: Dual GIP/GLP-1 receptor agonist
• Format: Lyophilized powder
• Strength: 10mg per vial
• Administration Route: Subcutaneous research application
• Storage Conditions: Refrigerated at 2–8°C, protected from light and excessive heat
• Solubility: Reconstitutable with bacteriostatic water or compatible research diluent

Tirzepatide has been extensively studied for its effects on metabolic regulation, insulin sensitivity, appetite modulation, and body weight management in clinical research settings. Current literature identifies tirzepatide as a first-in-class dual incretin mimetic with prolonged pharmacokinetic activity and strong receptor selectivity. (NCBI)